This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The company has received Form 483 with three observations
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Lupin enters into BTA with Lupin Manufacturing Solutions
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Increased capability to produce medicines for challenging diseases including cancer
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
